News | February 16, 2024
Marksans Q3 FY24 revenue up 22% at Rs 586 Cr
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
The company is strongly committed to enhancing customer satisfaction and catering to the discerning needs of renowned pharmaceutical companies
These re-agent and diagnostic test kits come with 99.7% accuracy
Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions
Gabapentin is indicated for the management of Postherpetic Neuraligia
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Pimavanserin is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson disease psychosis
The PAI was conducted for two drug product applications (ANDAs) filed from this facility
Ami Organics will also sign an MoU with Government of Gujarat for investment amounting up to Rs 300 crores for set up of dedicated manufacturing facility for electrolytes business
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
